Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

TSMC reported for Q1 2023

4/20/23 TSM

Nokia's Q1 profit grew by 32%

4/20/23 NOK

The Nokia announced a quarterly dividend

4/20/23 NOK

Severstal's sales in Q1 increased by 1%

4/20/23 CHMF

Ozon will double the number of pickup points at the expense of Russian Post offices

4/20/23 OZON

Tesla's Q1 profit fell by 23%

4/20/23 TSLA

Alcoa ended Q1 with a loss of $232 million

4/20/23 AA

IBM reported for Q1 2023

4/20/23 IBM

Maxar shareholders agree to sell company

4/19/23 MAXR

The Morgan Stanley announced a quarterly dividend

4/19/23 MS